
**OMNIBUS SOLICITATION OF THE
NATIONAL INSTITUTES OF HEALTH,
CENTERS FOR DISEASE CONTROL AND PREVENTION,
FOOD AND DRUG ADMINISTRATION, AND
ADMINISTRATION FOR CHILDREN AND FAMILIES FOR**

**SMALL BUSINESS INNOVATION
RESEARCH (SBIR)**

AND

**SMALL BUSINESS TECHNOLOGY
TRANSFER (STTR)**

GRANT APPLICATIONS

**NIH, CDC, FDA, and ACF Program Descriptions and
Research Topics**

SUBMISSION DATES

APRIL 5, AUGUST 5, AND DECEMBER 5, 2012

**(MAY 7, SEPTEMBER 7, 2012 AND JANUARY 7, 2013
FOR AIDS/AIDS-RELATED RESEARCH)**

**National Institutes of Health (SBIR and STTR)
Centers for Disease Control and Prevention (SBIR)
Food and Drug Administration (SBIR)
Administration for Children and Families (SBIR)**

NATIONAL CANCER INSTITUTE (NCI)

The goal of the NCI is to improve the current state of cancer care through advances in cancer research as well as enhancements in the prevention, diagnosis, and treatment of this disease. The Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs are NCI's engines of innovation for developing and commercializing novel technologies to better prevent, diagnose, and treat cancer while enhancing cancer research and control. NCI's SBIR and STTR Programs offer funding for therapeutic agents and devices, *in vitro* diagnostics, imaging, cancer prevention, cancer biology, cancer control and epidemiology, e-Health, and many more areas of interest to the NCI.

NCI's SBIR and STTR programs focus on research, development and delivery and are critical to achieving the institute's goals. These programs fund small business concerns to conduct innovative cancer research and development. The NCI SBIR Development Center is committed to helping small business concerns advance promising technologies towards the marketplace through grant funding as well as its initiatives designed to facilitate external investments and commercialization. NCI encourages all SBIR Phase II awardees to apply to the NIH Commercialization Assistance Program (CAP) to gain assistance in transferring their products to the marketplace. NCI is increasingly tracking the progress of its funded small business concerns and the products they develop. Funding priority will be given to those small business concerns that show not only the ability to develop products but also growth towards independence from the SBIR/STTR program.

The major NCI SBIR-STTR portfolio areas are listed below as a guide to general technology areas funded through the program. Applications proposing innovative cancer-related technologies, with strong commercial potential, that fall outside these topic areas are also invited through this omnibus solicitation.

Major NCI SBIR Portfolio Areas:

- Therapeutics (Small Molecules and Biologics)
- *In Vitro* Diagnostics
- Imaging Agents and Technologies
- Cancer Control and Digital Health
- Devices for Cancer Therapy
- Tools for Cancer Biology Research

For additional information on high priority technology areas, events, and programmatic initiatives, access the NCI SBIR homepage: <http://sbir.cancer.gov/>. In addition, please see the contact list at the end of the NCI section to identify the Program Director within the NCI SBIR Development Center who specializes in your technology area.

Limited Amount of Award

For budgetary, administrative, or programmatic reasons, NCI may not fund an application or may decrease the length of an award and/or the budget recommended by a review committee. Generally, NCI does not fund Phase I applications greater than \$300,000 total costs or project periods greater than 2 years; generally, NCI does not fund Phase II applications greater than \$2,000,000 total costs or project periods greater than 3 years. Applicants considering a requested budget greater than these limits are strongly encouraged to contact program staff before submitting an application.

Phase IIB SBIR Competing Renewal Awards

The NCI does not accept applications for Phase IIB SBIR competing renewal award through this solicitation. However, the NCI offers Phase IIB opportunities in the form of the NCI SBIR Bridge Award, which is announced via a separate funding solicitation. The SBIR Bridge Award is designed to support the next stage of development for previously funded NIH-wide SBIR Phase II projects in the areas of cancer therapeutics, imaging technologies, interventional devices, diagnostics and prognostics. The purpose of this award is to address the funding gap known as the "Valley of Death" between the end of the SBIR Phase II award and the subsequent round of financing needed to advance a product or service toward commercialization. To achieve this goal, the Bridge Award funding opportunity is specifically designed to incentivize partnerships between NIH's SBIR Phase II awardees and third-party investors and/or strategic partners. Competitive preference and funding priority will be given to applicants that demonstrate the ability to secure substantial independent third-party investor funds (i.e., third-party funds that equal or exceed the requested NCI funds).

Budgets up to \$1 million in total costs per year and project periods up to three years (a total of \$3 million over three years) may be requested from the NCI. Development efforts may include preclinical R&D needed for regulatory filings (e.g., IND or IDE) and/or clinical trials. NCI intends to commit up to \$10M for up to 10 new awards in FY2012.

To ensure that you will be notified upon the release of the NCI SBIR Bridge Award solicitation, please sign up for the [NCI mailing list](#). If you have any questions regarding the Bridge Award, please contact your Phase II program director.

For additional information on research topics, please contact a Program Officer with a relevant area of expertise:

Michael Weingarten, MA
Director, NCI SBIR Development Center
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: weingartenm@mail.nih.gov

Web site: <http://sbir.cancer.gov>

Ali Andalibi, PhD
Program Director and Team Leader
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: andalibia@mail.nih.gov

Area of expertise: Biologics, Small Molecules and Therapeutic Surgical Interventions

Gregory Evans, PhD
Program Director and Team Leader
Small Business Innovation Research Development Center SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: evansgl@mail.nih.gov

Area of expertise: Cancer Imaging, Cancer Control, and Digital Health

Andrew Kurtz, PhD

Program Director
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: kurtza@mail.nih.gov
Area of expertise: Biologics, Small Molecules, Nanotherapeutics, and Molecular Diagnostics

David Beylin, MS, MBA, DABSNM
Program Director
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: beylind@mail.nih.gov
Area of expertise: Cancer Imaging, Radiation Therapy and Image-Guided Interventions

Patricia Weber, DrPH
Program Director
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: weberpa@mail.nih.gov
Area of expertise: Digital Health, Epidemiology, Software Development related to Cancer Control & Population Sciences, and Therapeutics

Xing-Jian Lou, PhD
Program Director
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: loux@mail.nih.gov
Area of expertise: *In Vitro* Diagnostics and Bioinformatics

Deepa Narayanan, MS, CCDM
Program Director
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: Deepa.Narayanan@mail.nih.gov
Area of expertise: Cancer Imaging, Radiation Therapy, and Clinical Trials

Amir Rahbar, PhD, MBA
Program Director
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: amir_rahbar@nih.gov
Area of expertise: *In Vitro* Diagnostics, Biologics, Therapeutics and Proteomics

Todd Haim, PhD

Program Manager
Small Business Innovation Research Development Center (SBIR)
National Cancer Institute
6116 Executive Boulevard, Room 402, MSC 8332
Rockville, MD 20852
Email: Haimte@mail.nih.gov

Area of expertise: *In Vitro* Diagnostics and Therapeutics

For administrative and grants management questions, contact:

Mr. Allen Lo
Grants Management Specialist
MSC 7150
6120 Executive Blvd
Rockville, MD 20892-7150
(301) 496-8796 Fax: 301-496-8601
Email: loa2@mail.nih.gov

For NCI-related SBIR Information, visit: <http://sbir.cancer.gov>.